HPV vaccination in HIV infection

Charles Jn Lacey, Charles Jn Lacey

Abstract

Persons with HIV are at increased risk of HPV infection, HPV disease, and HPV-related cancers compared to HIV negative persons. In persons with HIV, immune responses to vaccination are often sub-optimal, and while these improve with ART, they often remain lower and decline more rapidly than in HIV-negative individuals. Although the evidence base to support the immunogenicity of HPV vaccines in HIV + ve persons is reasonable, the evidence base to support the efficacy of HPV vaccines in HIV + ve individuals is inconsistent. There is one study in HIV + ve men who have sex with men (MSM) which showed no effect, and two other studies, one in HIV + ve women and one in HIV + ve adolescents that showed reduced effectiveness. All these effectiveness studies used Gardasil 4 (G4). Two studies in HIV + ve persons have shown superior immunogenicity of Cervarix (which uses a TLR4 agonist adjuvant) compared to G4. Studies of Hepatitis B vaccines in HIV + ve persons have shown that either (i) increased number of doses (ii) increased vaccine dose, or (iii) TLR agonist adjuvanted vaccines, all produce increased immunogenicity compared to standard vaccine regimes. Therefore, questions remain as to optimal HPV vaccine regimes in HIV and further clinical trials with different HPV vaccine regimes are needed.

Copyright © 2019 The Author. Published by Elsevier B.V. All rights reserved.

References

    1. Worobey M., Gemmel M., Teuwen D.E., Haselkorn T., Kunstman K., Bunce M. Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature. 2008;455:661–664.
    1. British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults. 2015.
    1. Tugizov S. Human immunodeficiency virus-associated disruption of mucosal barriers and its role in HIV transmission and pathogenesis of HIV/AIDS disease. Tissue Barriers. 2016;4(3):e1159276.
    1. Kreimer A.R., Herrero R., Sampson J.N., Porras C., Lowy D.R., Schiller J.T. Evidence for single-dose protection by the bivalent HPV vaccine-Review of the Costa Rica HPV vaccine trial and future research studies. Vaccine. 2018;36:4774–4782.
    1. Irungu E., Mugo N., Ngure K., Njuguna R., Celum C., Farquhar C. Immune response to hepatitis B virus vaccination among HIV-1 infected and uninfected adults in Kenya. J. Infect. Dis. 2013;207:402–410.
    1. Cohen C., von Mollendorf C., de Gouveia L., Naidoo N., Meiring S., Quan V. Effectiveness of 7-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in HIV-infected and -uninfected children in South Africa: a matched case-control study. Clin. Infect. Dis. 2014;59:808–818.
    1. Cubas R., van Grevenynghe J., Wills S., Kardava L., Santich B.H., Buckner C.M. Reversible reprogramming of circulating memory T follicular helper cell function during chronic HIV infection. J. Immunol. 2015;195:5625–5636.
    1. Wilkin T.J., Chen H., Cespedes M.S., Leon-Cruz J.T., Godfrey C., Chiao E.Y. A randomized, placebo-controlled trial of the quadrivalent human papillomavirus vaccine in human immunodeficiency virus-infected adults aged 27 Years or older: AIDS clinical trials group protocol A5298. Clin. Infect. Dis. 2018;67:1339–1346.
    1. McClymont E., Lee M., Raboud J., Coutlée F., Walmsley S., Lipsky N. The efficacy of the quadrivalent human papillomavirus vaccine in girls and women living with HIV. Clin. Infect. Dis. 2019;68:788–794.
    1. Moscicki A.B., Karalius B., Tassiopoulos K., Yao T.J., Jacobson D.L., Patel K. Human papillomavirus antibody levels & quadrivalent vaccine clinical effectiveness in perinatally Human Immunodeficiency Virus-infected and exposed, uninfected youth. Clin. Infect. Dis. 2019;(Feb 21)
    1. Denny L., Hendricks B., Gordon C., Thomas F., Hezareh M., Dobbelaere K. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Vaccine. 2013;31:5745–5753.
    1. Cespedes M.S., Kang M., Kojic E.M., Umbleja T., Godfrey C., Webster-Cyriaque J.Y. Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1. Papillomavirus Res. 2018;6:15–21.
    1. Weinberg A., Huang S., Moscicki A.B., Saah A., Levin M.J. IMPAACT P1085 Protocol Team. Persistence of memory B-cell and T-cell responses to the quadrivalent HPV vaccine in HIV-infected children. AIDS. 2018;32:851–859.
    1. Weinberg A., Song L.Y., Saah A., Brown M., Moscicki A.B., Meyer W.A., 3rd Humoral, mucosal, and cell-mediated immunity against vaccine and non-vaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children. J. Infect. Dis. 2012;206:1309–1318.
    1. Ellsworth G.B., Lensing S.Y., Ogilvie C.B., Lee J.Y., Goldstone S.E., Berry-Lawhorn J.M. A delayed dose of quadrivalent human papillomavirus vaccine demonstrates immune memory in HIV-1-infected men. Papillomavirus Res. 2018;6:11–14.
    1. Faust H., Toft L., Sehr P., Müller M., Bonde J., Forslund O. Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines. Vaccine. 2016;34:1559–1565.
    1. Folschweiler N., Teixeira J., Joshi S., Goldani L., Supparatpinyo K., Basu P. EUROGIN Lisbon; 2018. End of Study Results of a 2 Year Multicountry Phase IV Randomized Comparative Study of the Immunogenicity and Safety of the AS04-HPV-16/18 Vaccine and the HPV-6/11/16/18 Vaccine in HIV-Positive Female Subjects Aged 15-25 Years. abstract 275.
    1. Einstein M.H., Levin M.J., Chatterjee A., Chakhtoura N., Takacs P., Catteau G. Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: follow-up through month 48 in a phase III randomized study. Hum. Vaccines Immunother. 2014;10(12):3455–3465.
    1. Cooper C.L., Angel J.B., Seguin I., Davis H.L., Cameron D.W. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term sero-protection for up to 5 years. Clin. Infect. Dis. 2008;46:1310–1314.
    1. Szarewski A., Skinner S.R., Garland S. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low risk HPV types (PATRICIA randomised trial): an unexpected observation. 2013;208:1391–1396.
    1. Howell-Jones R., Soldan K., Wetten S., Mesher D., Williams T., Gill O.N., Hughes G. Declining genital warts in young women in England associated with HPV 16/18 vaccination: an ecological study. J. Infect. Dis. 2013;208:1397–1403.
    1. Gilca V. Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - a randomized clinical trial. Vaccine. 2018;36:7017–7024.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj